Research SummaryKey Findings

What research findings exist for MT-I regarding skin pigmentation and phototolerance?

Short-term UV erythema dose-response weakened, supporting an in vivo photoprotective mechanism. Additional studies report: improved light tolerance and quality of life, reduced phototoxic reactions.[1] ↗ [2] ↗

Before ReadingStudy populations, species, formulations and delivery conditions each have a defined scope. Research on an ingredient does not establish that this site's product batches have been validated for efficacy in humans or veterinary use.
i

Currently, 3 original studies related to the theme of this page have been selected. The number of studies includes different designs, populations, or preparations, not commercial clinical efficacy ratings. This page is a usage-oriented positive data selection, not a systematic review or dosing recommendation. Historical studies, combination preparations, and special models are all separately indicated.

Comparison of study design and results

Results from different populations, species, materials, or follow-up times cannot be directly combined. The table below is a comparative summary of published data, not new experimental data.

LiteratureStudy subjects and designObservation and discoveryScope of Explanation
2026 · PMID 42678656Exploratory study in healthy humans; 16mg implantShort-term UV erythema dose-response weakened, supporting an in vivo photoprotective mechanism.Some minimal erythema changes not significant; does not represent clinical promise for tanning or skin cancer prevention.
2026 · PMID 41793078Real-world cohort of 20 EPP patients in AustriaImproved light tolerance and quality of life, reduced phototoxic reactions.Studies the clinical formulation of afamelanotide, not the standard MT-I lyophilized vial.
2025 · PMID 40082741German EPP patient observational cohortLonger-term observation supports light tolerance and quality of life benefits.Registered cohort, no randomized placebo control; need to confirm the corresponding structure of MT-I.

References

Human Study2026REF. 01

What was observed in the ultraviolet response study in healthy humans?

Research Findings

Short-term UV erythema dose-response weakened, supporting an in vivo photoprotective mechanism.[1] ↗

Study Design

Exploratory study in healthy humans; 16mg implant

Scope & Limitations

Some minimal erythema changes not significant; does not represent clinical promise for tanning or skin cancer prevention.

View the Article Title and Full Citation＋

Acute impact of afamelanotide on UVR erythemal and melanogenic responses in healthy humans in vivo: an exploratory study.

Griffin LL, Kiss O, Halai P, Langton AK, Rhodes LE, Farrar MD.

Photochemical & Photobiological Sciences: Official Journal of the European Photochemistry Association and the European Society for Photobiology · Volume and Issue Year 2026
First published 2026-09-01 · PMID 42678656
DOI 10.1007/s43630-026-00986-x

Published · Original ResearchPubMed ↗Journal Article ↗
Human Study2026REF. 02

How do light tolerance and quality of life change in EPP patients?

Research Findings

Improved light tolerance and quality of life, reduced phototoxic reactions.[2] ↗

Study Design

Real-world cohort of 20 EPP patients in Austria

Scope & Limitations

Studies the clinical formulation of afamelanotide, not the standard MT-I lyophilized vial.

View the Article Title and Full Citation＋

Afamelanotide improves quality of life and light tolerance in Austrian erythropoietic protoporphyria patients.

Seidl-Philipp M, Schratter H, Auer J, Schwantzer G, Lammer M, Hinteregger P, Vergeiner I, Gruber R, Wolf P, Hofer A.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology: JDDG · Volume/Issue/Year 2026
First published 2026-03-06 · PMID 41793078
DOI 10.1111/ddg.15996

Published · Original ResearchPubMed ↗Journal Article ↗
Human Study2025REF. 03

What do longer-term observations of the EPP cohort indicate?

Research Findings

Longer-term observation supports light tolerance and quality of life benefits.[3] ↗

Study Design

German EPP patient observational cohort

Scope & Limitations

Registered cohort, no randomized placebo control; need to confirm the corresponding structure of MT-I.

View the Article Title and Full Citation＋

German Cohort Observational Study to Investigate the Short- and Long-Term Safety and Clinical Effectiveness of Afamelanotide 16 mg (SCENESSE) in Patients With Erythropoietic Protoporphyria (EPP).

Homey B, Schelonke K, Schlegel CM, Bruch-Gerharz D, Weller K, Kiefer L, Stölzel U, Staubach-Renz P, Wegner J, Keller-Melchior R, Walker G, Bochno M, Bilbao P.

Photodermatology, Photoimmunology & Photomedicine · Volume and Issue Year 2025
First published 2025-03-01 · PMID 40082741
DOI 10.1111/phpp.13012

Published · Original ResearchPubMed ↗Journal Article ↗

Common issues and corresponding evidence

What research findings exist for MT-I regarding skin pigmentation and phototolerance?＋

Short-term UV erythema dose-response weakened, supporting an in vivo photoprotective mechanism. Additional studies report: improved light tolerance and quality of life, reduced phototoxic reactions.[1] ↗ [2] ↗

Is MT-I phototolerance research the same as everyday tanning evidence?＋

No. Most data studies Afamelanotide clinical formulations in EPP patients regarding light tolerance and quality of life; MT-I structure must also be verified, and the effect of implants cannot be taken as the tanning promise of ordinary lyophilized vials.[2] ↗ [3] ↗

MT-I—these conclusions apply to which study populations?＋

Exploratory study in healthy humans; 16 mg implant; real-world cohort of 20 EPP patients in Austria; observational cohort of EPP patients in Germany. Some minimal erythema dose changes were not significant; does not represent clinical commitment to tanning or skin cancer prevention.[1] ↗ [2] ↗ [3] ↗

MT-I

Return to catalog specifications and batch file verification entry.

↗